Atovaquone and azithromycin for the treatment of babesiosis.
Atovaquone and azithromycin for the treatment of babesiosis.
复制标题
DOI：
10.1056/nejm200011163432004
复制
发表时间：
2000-11-16
影响因子：
158.5
通讯作者：
Spielman, A
中科院分区：
文献类型：
--
作者：
Krause, PJ;Lepore, T;Spielman, A
背景：巴贝虫病是一种蜱传的、类似疟疾的疾病，已知在新英格兰南部流行。标准治疗是克林霉素和奎宁一个疗程，但这种治疗方案经常引起不良反应，有时甚至会失败。一种有前途的替代治疗方法是阿托伐醌加阿奇霉素。方法：我们对马萨诸塞州楠塔基特岛 58 名患有非危及生命的巴贝西虫病的受试者进行了一项前瞻性、非盲式、随机试验，对这两种方案进行了试验。罗德岛州布洛克岛；和康涅狄格州南部。受试者被分配接受阿托伐醌（每 12 小时 750 毫克）和阿奇霉素（第一天 500 毫克，此后每天 250 毫克）治疗 7 天（40 名受试者），或克林霉素（每 8 小时 600 毫克）和奎宁（每 8 小时 650 毫克）治疗 7 天（18 名受试者）。 结果：接受阿托伐醌和阿托伐醌治疗的受试者中有 15% 报告了不良反应。阿奇霉素，相比之下，接受克林霉素和奎宁治疗的患者中，这一比例为 72%（P
Background: Babesiosis is a tick-borne, malaria-like illness known to be enzootic in southern New England. A course of clindamycin and quinine is the standard treatment, but this regimen frequently causes adverse reactions and occasionally fails. A promising alternative treatment is atovaquone plus azithromycin.Methods: We conducted a prospective, nonblinded, randomized trial of the two regimens in 58 subjects with non-life-threatening babesiosis on Nantucket, Massachusetts; on Block Island, Rhode Island; and in southern Connecticut. The subjects were assigned to receive either atovaquone (750 mg every 12 hours) and azithromycin (500 mg on day 1 and 250 mg per day thereafter) for seven days (40 subjects) or clindamycin (600 mg every 8 hours) and quinine (650 mg every 8 hours) for seven days (18 subjects).Results: Adverse effects were reported by 15 percent of the subjects who received atovaquone and azithromycin, as compared with 72 percent of those who received clindamycin and quinine (P